share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Feb 21 17:52
Summary by Moomoo AI
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of 6,370 common shares on February 20, 2024, as per the latest SEC filings. The shares were sold at a price of $79.67 each, totaling approximately $507,498 in value. Prior to this sale, Kulkarni exercised options to acquire 13,250 shares on February 18, 2024, under a transaction classified as an exercise or conversion of derivative security. Following these transactions, Kulkarni directly holds 194,257 shares of the company. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an indirect holding entity.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of 6,370 common shares on February 20, 2024, as per the latest SEC filings. The shares were sold at a price of $79.67 each, totaling approximately $507,498 in value. Prior to this sale, Kulkarni exercised options to acquire 13,250 shares on February 18, 2024, under a transaction classified as an exercise or conversion of derivative security. Following these transactions, Kulkarni directly holds 194,257 shares of the company. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT, an indirect holding entity.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more